--- title: "基石药业宣布其新型三特异性抗体 CS2009（PD-1/VEGF/CTLA-4）的 IND 申请已获得 FDA 批准，即将进入 II 期临床试验" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276018493.md" description: "基石药业已获得 FDA 批准，启动其三特异性抗体 CS2009 的 IND 申请，以开展针对晚期实体瘤的第二阶段临床试验。该试验将评估单药治疗和联合治疗，涵盖 15 个队列和 9 个适应症，包括非小细胞肺癌和结直肠癌。初步的第一阶段数据表明其安全性良好，并且具有良好的抗肿瘤活性。目前该试验正在澳大利亚和中国招募患者，预计将在即将举行的肿瘤学大会上发布进一步更新" datetime: "2026-02-16T00:22:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276018493.md) - [en](https://longbridge.com/en/news/276018493.md) - [zh-HK](https://longbridge.com/zh-HK/news/276018493.md) --- # 基石药业宣布其新型三特异性抗体 CS2009（PD-1/VEGF/CTLA-4）的 IND 申请已获得 FDA 批准，即将进入 II 期临床试验 - CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received **Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)** **to initiate a Phase II clinical trial in** **patients with advanced solid tumors.** This marks a significant milestone in the global development of this innovative immunotherapy. - The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes **15 cohorts** evaluating both monotherapy and combination therapy regimens across **9 solid tumor indications**, including but not limited to: - Non-small cell lung cancer (NSCLC) - Colorectal cancer (CRC) - Triple-negative breast cancer (TNBC) - Extensive-stage small cell lung cancer (ES-SCLC)‌ - Platinum-resistant ovarian cancer (PROC) - Initial Phase I data for CS2009, previously presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting, **demonstrat****ed a favorable safety profile with encouraging antitumor activities.** Further clinical data from both the phase I and II is expected to be disclosed at the upcoming American Society of Clinical Oncology (ASCO) and ESMO congress later this year. SUZHOU, China, Feb. 15, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that **the U.S. FDA has** **cleared the IND application** **to initiate a Phase II clinical trial of its core asset, CS2009, in** **patients with advanced solid tumors.** **Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone,** stated, "We are pleased to receive FDA clearance to proceed with the global Phase II clinical trial of CS2009. This milestone follows a productive interaction with the agency, during which they reviewed our comprehensive Phase I data—including safety and antitumor activity data collected during dose escalation and expansion—and provided alignment on key elements of the Phase II study design, including dose optimization and expansion strategies. We are now actively advancing CS2009 clinical program globally and look forward to sharing further updates as the study progresses." **About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)** CS2009, an innovative trispecific antibody designed and developed by CStone, with the potential to be first- or best-in-class. It combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects through synergistic actions. Specifically, anti-PD-1 activity reverses T cell exhaustion, anti-CTLA-4 activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells. The ongoing global, multicenter Phase II clinical trial of CS2009 features a multi-cohort, parallel expansion design to evaluate the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of CS2009 as monotherapy and combination regimens. The study comprises 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including NSCLC, CRC, TNBC, ES-SCLC, PROC, cervical cancer (CC), hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), and esophageal squamous cell carcinoma (ESCC). The trial is actively enrolling patients in Australia and China and has received IND clearance in the U.S. **About CStone** CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com. **Forward-looking statements** The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. _Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes._ View original content:https://www.prnewswire.com/news-releases/cstone-announces-fda-clearance-of-ind-application-for-its-novel-trispecific-antibody-cs2009-pd-1vegfctla-4-to-advance-into-phase-ii-clinical-trial-302688307.html SOURCE CStone Pharmaceuticals ### 相关股票 - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [02616.HK](https://longbridge.com/zh-CN/quote/02616.HK.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [VRTX.US](https://longbridge.com/zh-CN/quote/VRTX.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [BMRN.US](https://longbridge.com/zh-CN/quote/BMRN.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) ## 相关资讯与研究 - [强生公司销售额增长近 10%，上调 2026 年业绩展望](https://longbridge.com/zh-CN/news/282850988.md) - [基石药业配股集资近 10.6 亿元](https://longbridge.com/zh-CN/news/282761807.md) - [募资 6.25 亿美元创五年之最 减肥药新贵 Kailera Therapeutics 今晚登陆纳斯达克](https://longbridge.com/zh-CN/news/283085982.md) - [东方证券：全球首个 pan-RAS 药物数据惊艳 突破胰腺癌治疗困局](https://longbridge.com/zh-CN/news/282928576.md) - [OpenAI 推出药物研发 AI 模型 挑战谷歌](https://longbridge.com/zh-CN/news/283053858.md)